Literature DB >> 28509161

Use of LightCycler mutation analysis to detect type II adenine phosphoribosyltransferase deficiency in two patients with 2,8-dihydroxyadeninuria.

Hirokazu Ikeda1, Tuneki Watanabe2, Daiske Toyama2, Keiichi Isoyama2.   

Abstract

Recently, a number of methods have been devised for detection of mutations in the field of molecular genetics. The LightCycler system has been used for rapid PCR, while simultaneously quantifying and analyzing the amplification results. We tried to apply the LightCycler system to detect APRT*J allele mutations in two families including two children with 2,8-dihydroxyadenine urolithiasis. The first patient was a 3-year-old girl who presented with left flank pain. The second patient was a 2-year-old girl who presented with complaints of sudden dysuria. The spectrophotometric analysis of the stone fragments of both patients revealed an absorption spectrum for 2,8-DHA. We used the LightCycler system to detect APRT*J mutation. The first patient was homozygous for APRT*J/APRT*J and the second patient was compound heterozygous for APRT*J/APRT*Q0. The genetic diagnosis of APRT deficiency using this system may be useful not only as a diagnostic test for infants with known 2,8-DHA, but also as a screening of infants with a suspicion of urolithiasis. We believed that the LightCycler system still is an important means of identifying APRT*J mutation.

Entities:  

Keywords:  2,8-Dihydroxyadeninuria; Adenine phosphoribosyltransferase deficiency; Child; LightCycler; Real-time PCR instruments; Urolithiasis

Year:  2015        PMID: 28509161      PMCID: PMC5411657          DOI: 10.1007/s13730-015-0186-x

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  9 in total

1.  Rapid genotyping of hemochromatosis gene mutations on the LightCycler with fluorescent hybridization probes.

Authors:  K Mangasser-Stephan; C Tag; A Reiser; A M Gressner
Journal:  Clin Chem       Date:  1999-10       Impact factor: 8.327

2.  Use of real-time quantitative PCR to compare DNA isolation methods.

Authors:  J B de Kok; J C Hendriks; W W van Solinge; H L Willems; E J Mensink; D W Swinkels
Journal:  Clin Chem       Date:  1998-10       Impact factor: 8.327

3.  Continuous fluorescence monitoring of rapid cycle DNA amplification.

Authors:  C T Wittwer; M G Herrmann; A A Moss; R P Rasmussen
Journal:  Biotechniques       Date:  1997-01       Impact factor: 1.993

4.  Acute renal failure in a middle-aged woman with 2,8-dihydroxyadeninuria.

Authors:  M Arnadottir; T Laxdal; S Hardarson; P Asmundsson
Journal:  Nephrol Dial Transplant       Date:  1997-09       Impact factor: 5.992

5.  Detection of mutations in adenine phosphoribosyltransferase (APRT) deficiency using the LightCycler system.

Authors:  T Funato; Y Nishiyama; N Ioritani; R Matsuki; K Yoshida; M Kaku; T Sasaki; H Ideguchi; J Ono
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

6.  Only three mutations account for almost all defective alleles causing adenine phosphoribosyltransferase deficiency in Japanese patients.

Authors:  N Kamatani; M Hakoda; S Otsuka; H Yoshikawa; S Kashiwazaki
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

7.  Adenine phosphoribosyltransferase deficiency identified by urinary sediment analysis: cellular and molecular confirmation.

Authors:  C Terai; M Hakoda; H Yamanaka; N Kamatani; M Okai; F Takahashi; S Kashiwazaki
Journal:  Clin Genet       Date:  1995-11       Impact factor: 4.438

8.  Genetic and clinical studies on 19 families with adenine phosphoribosyltransferase deficiencies.

Authors:  N Kamatani; C Terai; S Kuroshima; K Nishioka; K Mikanagi
Journal:  Hum Genet       Date:  1987-02       Impact factor: 4.132

9.  Common characteristics of mutant adenine phosphoribosyltransferases from four separate Japanese families with 2,8-dihydroxyadenine urolithiasis associated with partial enzyme deficiencies.

Authors:  S Fujimori; I Akaoka; K Sakamoto; H Yamanaka; K Nishioka; N Kamatani
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.